Please login to the form below

Not currently logged in
Email:
Password:

Former Novartis president joins Qu Biologics

Robert Pelzer is appointed board member at immunotherapy specialists

Qu Biologics Robert Pelzer

Qu Biologics has appointed former president of Novartis' US operations Robert Pelzer to its board of directors.

Pelzer was appointed president of Novartis Corporation in 2008, holding responsibility for Novartis' operations in North America.

He was previously global general counsel and head of legal services for Novartis at a corporate level.

Before joining Novartis in 2002, he spent several years at DuPont Pharmaceuticals, serving as general counsel and senior VP.

His senior industry experience will support Qu Biologics' plans to advance the development of its investigational immunotherapies for treatments such as Crohn's disease.

“Bob Pelzer's wealth of leadership experience with Novartis and DuPont will be invaluable to Qu Biologics during this important stage of our growth and development,” said CEO of Qu Biologics Dr Hal Gunn, who also noted that Pelzer will help develop relationships with potential pharma partners.

18th June 2013

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...
clinical research org
The important role of CROs in shaping the future of clinical research across Europe
Looking at the impact of COVID-19 on clinical research activities...
What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...

Infographics